Your browser doesn't support javascript.
loading
Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study.
Cuthbert, Joseph James; Soyiri, Ireneous; Lomax, Stephanie Jayne; Turgoose, John; Fuat, Ahmet; Cohen, Judith; Clark, Andrew L.
Afiliação
  • Cuthbert JJ; Clinical Sciences Centre, Hull York Medical School, University of Hull, Hull, UK joe.cuthbert@hyms.ac.uk.
  • Soyiri I; Department of Cardiology, Castle Hill Hospital, Cottingham, UK.
  • Lomax SJ; Institute for Clinical and Applied Health Research, Hull York Medical School, University of Hull, Hull, UK.
  • Turgoose J; Cottingham Medical Centre, Cottingham, UK.
  • Fuat A; Hull Health Trials Unit, Hull York Medical School, University of Hull, Hull, UK.
  • Cohen J; GP, County Durham and Darlington NHS Foundation Trust, Darlington Memorial Hospital, Darlington, UK.
  • Clark AL; Institute for Clinical and Applied Health Research, Hull York Medical School, University of Hull, Hull, UK.
Heart ; 110(12): 854-862, 2024 May 23.
Article em En | MEDLINE | ID: mdl-38631899
ABSTRACT

BACKGROUND:

Loop diuretics are commonly prescribed in the community, not always to patients with a recorded diagnosis of heart failure (HF). The rate of HF events in patients prescribed loop diuretics without a diagnosis of HF is unknown.

METHODS:

This was a propensity-matched cohort study using data from the Clinical Practice Research Datalink, Hospital Episode Statistics and Office of National Statistics in the UK. Patients prescribed a loop diuretic without a diagnosis of HF (loop diuretic group) between 1 January 2010 and 31 December 2015 were compared with patients with HF (HF group)-analysis A, and patients with risk factors for HF (either ischaemic heart disease, or diabetes and hypertension-at-risk group)-analysis B. The primary endpoint was an HF event (a composite of presentation with HF symptoms, HF hospitalisation, HF diagnosis (analysis B only) and all-cause mortality).

RESULTS:

From a total population of 180 384 patients (78 968 in the loop diuretic group, 28 177 in the HF group and 73 239 in the at-risk group), there were 59 694 patients, 22 352 patients and 57 219 patients in the loop diuretic, HF and at-risk groups, respectively, after exclusion criteria were applied. After propensity matching for age, sex and comorbidities, patients in the loop diuretic group had a similar rate of HF events as those in the HF group (71.9% vs 72.1%; HR=0.92 (95% CI 0.90 to 0.94); p<0.001), and twice as those in the at-risk group (59.2% vs 35.7%; HR=2.04 (95% CI 2.00 to 2.08); p<0.001).

CONCLUSIONS:

Patients prescribed a loop diuretic without a recorded diagnosis of HF experience HF events at a rate comparable with that of patients with a recorded diagnosis of HF; many of these patients may have undiagnosed HF.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Simportadores de Cloreto de Sódio e Potássio / Insuficiência Cardíaca Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Simportadores de Cloreto de Sódio e Potássio / Insuficiência Cardíaca Idioma: En Ano de publicação: 2024 Tipo de documento: Article